A. Hasselblatt

1.6k total citations
67 papers, 892 citations indexed

About

A. Hasselblatt is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery. According to data from OpenAlex, A. Hasselblatt has authored 67 papers receiving a total of 892 indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Molecular Biology, 22 papers in Endocrinology, Diabetes and Metabolism and 19 papers in Surgery. Recurrent topics in A. Hasselblatt's work include Pancreatic function and diabetes (19 papers), Metabolism, Diabetes, and Cancer (15 papers) and Diet, Metabolism, and Disease (10 papers). A. Hasselblatt is often cited by papers focused on Pancreatic function and diabetes (19 papers), Metabolism, Diabetes, and Cancer (15 papers) and Diet, Metabolism, and Disease (10 papers). A. Hasselblatt collaborates with scholars based in Germany and Czechia. A. Hasselblatt's co-authors include Axel Schulz, U. Panten, W. Poser, Hans‐Georg Joost, Sigurd Lenzen, Julian K. Christians, U. Schwabe, J Schönborn, Ingo Rustenbeck and B. Müller‐Oerlinghausen and has published in prestigious journals such as The Journal of Physiology, Analytical Biochemistry and FEBS Letters.

In The Last Decade

A. Hasselblatt

64 papers receiving 811 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Hasselblatt Germany 16 456 440 304 187 157 67 892
Leonard Best United Kingdom 20 586 1.3× 631 1.4× 348 1.1× 160 0.9× 214 1.4× 45 1.1k
Gustaf N. Hendrick United States 14 374 0.8× 522 1.2× 589 1.9× 141 0.8× 312 2.0× 18 1.1k
Habiba Najafi United States 14 476 1.0× 566 1.3× 306 1.0× 50 0.3× 157 1.0× 15 859
Jorge Tamarit‐Rodriguez Spain 15 462 1.0× 738 1.7× 362 1.2× 77 0.4× 245 1.6× 37 1.0k
Kirsten Capito Denmark 20 608 1.3× 770 1.8× 370 1.2× 59 0.3× 219 1.4× 51 1.1k
F. Assimacopoulos Switzerland 3 429 0.9× 179 0.4× 118 0.4× 101 0.5× 285 1.8× 4 779
W. S. Zawalich United States 21 802 1.8× 1.1k 2.6× 794 2.6× 98 0.5× 188 1.2× 50 1.5k
P Detimary Belgium 11 533 1.2× 825 1.9× 360 1.2× 86 0.5× 135 0.9× 13 1000
Frank Stümpel Germany 17 604 1.3× 205 0.5× 187 0.6× 136 0.7× 168 1.1× 29 1.0k
Steven Patterson United Kingdom 15 313 0.7× 265 0.6× 355 1.2× 169 0.9× 149 0.9× 35 779

Countries citing papers authored by A. Hasselblatt

Since Specialization
Citations

This map shows the geographic impact of A. Hasselblatt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Hasselblatt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Hasselblatt more than expected).

Fields of papers citing papers by A. Hasselblatt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Hasselblatt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Hasselblatt. The network helps show where A. Hasselblatt may publish in the future.

Co-authorship network of co-authors of A. Hasselblatt

This figure shows the co-authorship network connecting the top 25 collaborators of A. Hasselblatt. A scholar is included among the top collaborators of A. Hasselblatt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Hasselblatt. A. Hasselblatt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hasselblatt, A.. (2015). Pharmacokinetics of Insulin and Oral Antidiabetic Drugs in Renal Insufficiency. Contributions to nephrology. 73. 139–146.
2.
Rustenbeck, Ingo, et al.. (2009). Effects of Imidazoline Compounds on Cytoplasmic Ca2+ concentration and ATP-sensitive K+ channels in Pancreatic B-cells. Experimental and Clinical Endocrinology & Diabetes. 103(S 02). 42–45. 4 indexed citations
3.
Rustenbeck, Ingo, et al.. (1999). Heterogeneous characteristics of imidazoline-induced insulin secretion. Naunyn-Schmiedeberg s Archives of Pharmacology. 359(3). 235–242. 11 indexed citations
4.
Rustenbeck, Ingo, et al.. (1999). Imidazolines and the Pancreatic B‐Cell: Actions and Binding Sites. Annals of the New York Academy of Sciences. 881(1). 229–240. 7 indexed citations
5.
Rustenbeck, Ingo, et al.. (1998). No evidence for PKC activation in stimulation of insulin secretion by phentolamine. Naunyn-Schmiedeberg s Archives of Pharmacology. 358(3). 390–393. 7 indexed citations
6.
Rustenbeck, Ingo, et al.. (1997). Imidazoline/guanidinium binding sites and their relation to inhibition of KATP channels in pancreatic B-cells. Naunyn-Schmiedeberg s Archives of Pharmacology. 356(3). 410–417. 30 indexed citations
7.
Schulz, Axel & A. Hasselblatt. (1989). An insulin-releasing property of imidazoline derivatives is not limited to compounds that block ?-adrenoceptors. Naunyn-Schmiedeberg s Archives of Pharmacology. 340(3). 321–7. 108 indexed citations
8.
Schulz, Axel & A. Hasselblatt. (1989). Dual action of clonidine on insulin release: suppression, but stimulation when ?2-adrenoceptors are blocked. Naunyn-Schmiedeberg s Archives of Pharmacology. 340(6). 712–714. 45 indexed citations
9.
Schulz, Axel & A. Hasselblatt. (1988). Phentolamine, a deceptive tool to investigate sympathetic nervous control of insulin release. Naunyn-Schmiedeberg s Archives of Pharmacology. 337(6). 637–43. 62 indexed citations
10.
Joost, Hans‐Georg & A. Hasselblatt. (1977). Effects of polymer-linked sulfonylurea derivatives on insulin release. Naunyn-Schmiedeberg s Archives of Pharmacology. 297(1). 81–84. 5 indexed citations
11.
Lenzen, Sigurd, Hans‐Georg Joost, & A. Hasselblatt. (1976). The inhibition of insulin secretion from the perfused rat pancreas after thyroxine treatment. Diabetologia. 12(5). 495–500. 11 indexed citations
12.
Lenzen, Sigurd, U. Panten, & A. Hasselblatt. (1975). Thyroxine treatment and insulin secretion in the rat. Diabetologia. 11(1). 49–55. 34 indexed citations
13.
Schönborn, J, W. Poser, U. Panten, & A. Hasselblatt. (1974). Effect of Hypoglycemic Sulfonylureas on Hepatic Fructose Metabolism in the Rat. Hormone and Metabolic Research. 6(4). 284–289. 8 indexed citations
14.
Hasselblatt, A., U. Panten, & W. Poser. (1969). [Effect of tolbutamide and HB 419 on blood glucose, plasma-corticosterone and liver glycogen in rats].. PubMed. 19(8). Suppl:1483–7. 2 indexed citations
15.
Schwabe, U., et al.. (1968). Hemmung der Lipolyse im Fettgewebe durch Methylisoxazolcarbons�uren. Naunyn-Schmiedeberg s Archives of Pharmacology. 260(1). 1–15. 6 indexed citations
16.
Müller‐Oerlinghausen, B., A. Hasselblatt, & Roland Jahns. (1968). Enhanced formation of bilirubin glucuronide in the liver during insulin and sulfonylurea hypoglycemia.. PubMed. 260(2). 254–68. 1 indexed citations
17.
Hasselblatt, A.. (1967). Die Hemmung der Ketonk�rperbildung im Lebergewebe durch in vitro zugesetzte blutzuckersenkende Pharmaka. Naunyn-Schmiedeberg s Archives of Pharmacology. 257(3). 281–281. 3 indexed citations
18.
Hasselblatt, A., et al.. (1965). Die Wirkung von Tolbutamid und verwandten Verbindungen auf die Aufnahme von Bromsulphalein (BSP, Bromthalein) durch inkubiertes Lebergewebe. Journal of Molecular Medicine. 43(4). 220–225. 5 indexed citations
19.
Hasselblatt, A. & G. Bastian. (1958). [Comparative studies on the convulsive effects of insulin and N1-(4-methylbenzene-sulfonyl)-N2-butylurea in mice under normal metabolic conditions and conditions altered by thyroxin treatment].. PubMed. 8(9). 590–4. 3 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Leonard Best Breakdown of academic impact, for papers by Gustaf N. Hendrick Breakdown of academic impact, for papers by Habiba Najafi Breakdown of academic impact, for papers by Jorge Tamarit‐Rodriguez Breakdown of academic impact, for papers by Kirsten Capito Breakdown of academic impact, for papers by F. Assimacopoulos Breakdown of academic impact, for papers by W. S. Zawalich Breakdown of academic impact, for papers by P Detimary Breakdown of academic impact, for papers by Frank Stümpel Breakdown of academic impact, for papers by Steven Patterson
Rankless by CCL
2026